Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.570
-0.070 (-1.92%)
At close: Aug 15, 2025, 4:00 PM
3.670
+0.100 (2.80%)
After-hours: Aug 15, 2025, 7:59 PM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
The 4 analysts that cover Prime Medicine stock have a consensus rating of "Buy" and an average price target of $8.88, which forecasts a 148.74% increase in the stock price over the next year. The lowest target is $1.50 and the highest is $18.
Price Target: $8.88 (+148.74%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +180.11% | Aug 8, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $10 → $1.5 | Strong Buy → Hold | Downgrades | $10 → $1.5 | -57.98% | May 27, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +68.07% | May 20, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 20, 2025 |
Financial Forecast
Revenue This Year
6.77M
from 2.98M
Increased by 126.92%
Revenue Next Year
12.68M
from 6.77M
Increased by 87.32%
EPS This Year
-1.32
from -1.65
EPS Next Year
-1.03
from -1.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.9M | 84.0M | 141.8M | ||
| Avg | 6.8M | 12.7M | 30.5M | ||
| Low | 1.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 533.6% | 1,141.0% | 1,017.9% | ||
| Avg | 126.9% | 87.3% | 140.8% | ||
| Low | -52.4% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.18 | -0.80 | -0.48 | ||
| Avg | -1.32 | -1.03 | -0.95 | ||
| Low | -1.57 | -1.57 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.